Exhibit 99.1 Anaphylm is an oral epinephrine product candidate being developed for the treatment of type I allergic reactions, including anaphylaxis. The Company believes Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine product for the treatment of type I allergic reactions, including anaphylaxis, if approved by the U.S. Food and Drug Administration (FDA). On September 16, 2026, the Company resubmitted its New Drug Application (NDA) for Anaphylm to the U.S. Food ...